Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability

Curtis D Collins1, Sarah Cookinham2, Jeannina Smith21Department of Pharmacy Services, 2Department of Medicine, Division of Infectious Disease, University of Michigan Health System, Ann Arbor, MI, USAAbstract: Oropharyngeal candidiasis is a very common localized infection of the mucus membranes of th...

Full description

Bibliographic Details
Main Authors: Cookinham S, Collins CD, Smith J
Format: Article
Language:English
Published: Dove Medical Press 2011-07-01
Series:Patient Preference and Adherence
Online Access:http://www.dovepress.com/management-of-oropharyngeal-candidiasis-with-localized-oral-miconazole-a7899
id doaj-790c90d3b5b74263aef131c90d905a17
record_format Article
spelling doaj-790c90d3b5b74263aef131c90d905a172020-11-24T22:09:17ZengDove Medical PressPatient Preference and Adherence1177-889X2011-07-012011default369374Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptabilityCookinham SCollins CDSmith JCurtis D Collins1, Sarah Cookinham2, Jeannina Smith21Department of Pharmacy Services, 2Department of Medicine, Division of Infectious Disease, University of Michigan Health System, Ann Arbor, MI, USAAbstract: Oropharyngeal candidiasis is a very common localized infection of the mucus membranes of the oropharynx that is most commonly caused by the patient's own commensal Candida albicans. It is the most common opportunistic infection affecting patients with the human immunodeficiency virus (HIV) and is also quite common in patients with hematological malignancies. Effective treatment options are of high importance given the worldwide incidence of these disease states and the potential for development of oropharyngeal candidiasis in these patients. Various systemic and topical treatment options for patients with oropharyngeal candidiasis have existed for many years. Miconazole buccal tablets have recently been approved by the US Food and Drug Administration for the treatment of oropharyngeal candidiasis. Clinical trials have demonstrated noninferiority in the treatment of oropharyngeal candidiasis when compared with clotrimazole troches in patients with HIV and against miconazole gel in patients with head and neck cancer. Miconazole buccal tablets exhibit few drug interactions because of low systemic absorption and are generally well tolerated with a safety profile similar to comparators. The once-daily dosing schedule may improve patient adherence compared with topical alternatives; however, the cost of therapy may be a barrier for some patients and should be considered by prescribers compared with alternative treatments.Keywords: esophageal candidiasis, miconazole, antifungal agentshttp://www.dovepress.com/management-of-oropharyngeal-candidiasis-with-localized-oral-miconazole-a7899
collection DOAJ
language English
format Article
sources DOAJ
author Cookinham S
Collins CD
Smith J
spellingShingle Cookinham S
Collins CD
Smith J
Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
Patient Preference and Adherence
author_facet Cookinham S
Collins CD
Smith J
author_sort Cookinham S
title Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
title_short Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
title_full Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
title_fullStr Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
title_full_unstemmed Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
title_sort management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
publisher Dove Medical Press
series Patient Preference and Adherence
issn 1177-889X
publishDate 2011-07-01
description Curtis D Collins1, Sarah Cookinham2, Jeannina Smith21Department of Pharmacy Services, 2Department of Medicine, Division of Infectious Disease, University of Michigan Health System, Ann Arbor, MI, USAAbstract: Oropharyngeal candidiasis is a very common localized infection of the mucus membranes of the oropharynx that is most commonly caused by the patient's own commensal Candida albicans. It is the most common opportunistic infection affecting patients with the human immunodeficiency virus (HIV) and is also quite common in patients with hematological malignancies. Effective treatment options are of high importance given the worldwide incidence of these disease states and the potential for development of oropharyngeal candidiasis in these patients. Various systemic and topical treatment options for patients with oropharyngeal candidiasis have existed for many years. Miconazole buccal tablets have recently been approved by the US Food and Drug Administration for the treatment of oropharyngeal candidiasis. Clinical trials have demonstrated noninferiority in the treatment of oropharyngeal candidiasis when compared with clotrimazole troches in patients with HIV and against miconazole gel in patients with head and neck cancer. Miconazole buccal tablets exhibit few drug interactions because of low systemic absorption and are generally well tolerated with a safety profile similar to comparators. The once-daily dosing schedule may improve patient adherence compared with topical alternatives; however, the cost of therapy may be a barrier for some patients and should be considered by prescribers compared with alternative treatments.Keywords: esophageal candidiasis, miconazole, antifungal agents
url http://www.dovepress.com/management-of-oropharyngeal-candidiasis-with-localized-oral-miconazole-a7899
work_keys_str_mv AT cookinhams managementoforopharyngealcandidiasiswithlocalizedoralmiconazoletherapyefficacysafetyandpatientacceptability
AT collinscd managementoforopharyngealcandidiasiswithlocalizedoralmiconazoletherapyefficacysafetyandpatientacceptability
AT smithj managementoforopharyngealcandidiasiswithlocalizedoralmiconazoletherapyefficacysafetyandpatientacceptability
_version_ 1725812768132562944